Lurasidone
Atypical antipsychotic medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Lurasidone?
Summarize this article for a 10 year old
Lurasidone, sold under the brand name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder.[2] It is taken by mouth.
Clinical data | |
---|---|
Pronunciation | /ljʊəˈræsɪˌdoʊn/ |
Trade names | Latuda, others |
Other names | SM-13496 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611016 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Atypical antipsychotic[2] |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 9–19% (oral)[3] |
Protein binding | ~99%[9] |
Metabolism | Liver (CYP3A4-mediated)[3] |
Elimination half-life | 18–40 hours[3][9] |
Excretion | Faecal (67–80%), renal (9–19%)[3][9] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.225.187 |
Chemical and physical data | |
Formula | C28H36N4O2S |
Molar mass | 492.68 g·mol−1 |
3D model (JSmol) | |
Specific rotation | [α]20D −59° |
Melting point | 176 to 178 °C (349 to 352 °F) |
Solubility in water | 0.224 |
| |
|
Common side effects include sleepiness, movement disorders, nausea, and diarrhea.[2] Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, angioedema, and high blood sugar levels,[10] although lurasidone is less likely to cause high blood sugar levels in most patients, hyperosmolar hyperglycemic syndrome may occur.[2][11][12] In older people with psychosis as a result of dementia, it may increase the risk of dying.[2] Use during pregnancy is of unclear safety.[13][14]
Lurasidone was first approved for medical use in the United States in 2010.[2] In 2013, it was approved in Canada, and by the United States Food and Drug Administration, to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate.[15][16] Generic versions were approved in the United States in 2019, and became available in 2023.[17][18] In 2021, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[19][20]